JP4611745B2 - ＥｒｂＢ２及びＥＧＦＲ阻害剤としてのシアノグアニジン及びシアノアミジン - Google Patents
ＥｒｂＢ２及びＥＧＦＲ阻害剤としてのシアノグアニジン及びシアノアミジン Download PDFInfo
- Publication number
- JP4611745B2 JP4611745B2 JP2004553551A JP2004553551A JP4611745B2 JP 4611745 B2 JP4611745 B2 JP 4611745B2 JP 2004553551 A JP2004553551 A JP 2004553551A JP 2004553551 A JP2004553551 A JP 2004553551A JP 4611745 B2 JP4611745 B2 JP 4611745B2
- Authority
- JP
- Japan
- Prior art keywords
- heteroaryl
- aryl
- heterocyclyl
- alkyl
- arylalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- QWGIRWNRJPYKAJ-UHFFFAOYSA-N Cc(cc(cc1)Nc2ncnc(cc3)c2cc3-c2c[s]c(CN/C(/N)=N\C#N)n2)c1Oc1ccc(C)nc1 Chemical compound Cc(cc(cc1)Nc2ncnc(cc3)c2cc3-c2c[s]c(CN/C(/N)=N\C#N)n2)c1Oc1ccc(C)nc1 QWGIRWNRJPYKAJ-UHFFFAOYSA-N 0.000 description 1
- HAHMFVLXQADNCA-UHFFFAOYSA-N N#C/N=C(\NCC#Cc(cc1)cc2c1ncnc2Nc1ccc2[n](CC(C=CC3)=CC3F)ncc2c1)/N1CCOCC1 Chemical compound N#C/N=C(\NCC#Cc(cc1)cc2c1ncnc2Nc1ccc2[n](CC(C=CC3)=CC3F)ncc2c1)/N1CCOCC1 HAHMFVLXQADNCA-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42754402P | 2002-11-20 | 2002-11-20 | |
| PCT/US2003/035670 WO2004046101A2 (en) | 2002-11-20 | 2003-11-10 | Cyanoguanidines and cyanoamidines as erbb2 and egfr inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006508979A JP2006508979A (ja) | 2006-03-16 |
| JP2006508979A5 JP2006508979A5 (enrdf_load_stackoverflow) | 2006-08-03 |
| JP4611745B2 true JP4611745B2 (ja) | 2011-01-12 |
Family
ID=32326558
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004553551A Expired - Fee Related JP4611745B2 (ja) | 2002-11-20 | 2003-11-10 | ＥｒｂＢ２及びＥＧＦＲ阻害剤としてのシアノグアニジン及びシアノアミジン |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1567506A4 (enrdf_load_stackoverflow) |
| JP (1) | JP4611745B2 (enrdf_load_stackoverflow) |
| AU (1) | AU2003291394B2 (enrdf_load_stackoverflow) |
| CA (1) | CA2506503A1 (enrdf_load_stackoverflow) |
| NZ (1) | NZ540092A (enrdf_load_stackoverflow) |
| WO (1) | WO2004046101A2 (enrdf_load_stackoverflow) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6562319B2 (en) | 2001-03-12 | 2003-05-13 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy |
| KR20080014144A (ko) * | 2003-08-18 | 2008-02-13 | 화이자 프로덕츠 인크. | ｅｒｂＢ２ 항암제에 대한 투약 스케쥴 |
| WO2005023315A2 (en) * | 2003-09-11 | 2005-03-17 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Radiolabeled anilinoquinazolines and their use in radioimaging and radiotherapy |
| GB0326459D0 (en) | 2003-11-13 | 2003-12-17 | Astrazeneca Ab | Quinazoline derivatives |
| CN101056639A (zh) | 2004-09-15 | 2007-10-17 | 詹森药业有限公司 | 噻唑并吡啶激酶抑制剂 |
| WO2006118749A1 (en) | 2005-05-04 | 2006-11-09 | Janssen Pharmaceutica, N.V. | Thia-tetraazaacenaphthylene kinase inhibitors |
| DE102006012251A1 (de) * | 2006-03-15 | 2007-11-08 | Grünenthal GmbH | Substituierte 4-Amino-chinazolin-Derivate und ihre Verwendung zur Herstellung von Arzneimitteln |
| US7851623B2 (en) | 2006-11-02 | 2010-12-14 | Astrazeneca Ab | Chemical process |
| MY150054A (en) | 2007-10-29 | 2013-11-29 | Natco Pharma Ltd | Novel 4-(tetrazol-5-yl)-quinazoline derivatives as anti cancer agents |
| KR20120090025A (ko) * | 2009-07-02 | 2012-08-16 | 뉴젠 세러퓨틱스 인코포레이티드 | 인 함유 퀴나졸린 화합물 및 그것의 사용 방법 |
| EP2956138B1 (en) | 2013-02-15 | 2022-06-22 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
| BR112015020139A2 (pt) | 2013-02-20 | 2017-07-18 | Kala Pharmaceuticals Inc | compostos terapêuticos e usos dos mesmos |
| US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
| MX355330B (es) | 2013-11-01 | 2018-04-16 | Kala Pharmaceuticals Inc | Formas cristalinas de compuestos terapeuticos y sus usos. |
| US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| US10710968B2 (en) | 2016-01-13 | 2020-07-14 | Hadasit Medical Research Services And Development Ltd. | Radiolabeled erlotinib analogs and uses thereof |
| US10253036B2 (en) | 2016-09-08 | 2019-04-09 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| CA3036340A1 (en) | 2016-09-08 | 2018-03-15 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| WO2018048746A1 (en) | 2016-09-08 | 2018-03-15 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| CN108285421A (zh) * | 2018-01-26 | 2018-07-17 | 黑龙江鑫创生物科技开发有限公司 | 一种微通道反应器合成拉帕替尼中间体的方法 |
| KR20220110235A (ko) | 2019-12-02 | 2022-08-05 | 아카데미아 시니카 | PDIA4 저해제 및 β-세포 발병을 저해하고 당뇨병을 치료하기 위한 이의 용도 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE446955T1 (de) * | 1995-03-30 | 2009-11-15 | Pfizer Prod Inc | Chinazolinone derivate |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| DK0880508T3 (da) * | 1996-02-13 | 2003-06-30 | Astrazeneca Ab | Quinazolinderivater som VEGF-inhibitorer |
| HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
| WO1999051582A1 (fr) | 1998-03-31 | 1999-10-14 | Kyowa Hakko Kogyo Co., Ltd. | Composes heterocycliques azotes |
| GB2345486A (en) | 1999-01-11 | 2000-07-12 | Glaxo Group Ltd | Heteroaromatic protein tyrosine kinase inhibitors |
| UA71945C2 (en) | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
| AP2001002192A0 (en) | 2000-06-22 | 2002-12-21 | Pfizer Prod Inc | Substituted bicyclic derivatives for the treatment of abnormal cell growth. |
-
2003
- 2003-11-10 AU AU2003291394A patent/AU2003291394B2/en not_active Expired - Fee Related
- 2003-11-10 NZ NZ540092A patent/NZ540092A/en not_active IP Right Cessation
- 2003-11-10 WO PCT/US2003/035670 patent/WO2004046101A2/en active Application Filing
- 2003-11-10 EP EP03768789A patent/EP1567506A4/en not_active Withdrawn
- 2003-11-10 JP JP2004553551A patent/JP4611745B2/ja not_active Expired - Fee Related
- 2003-11-10 CA CA002506503A patent/CA2506503A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004046101A2 (en) | 2004-06-03 |
| NZ540092A (en) | 2007-06-29 |
| CA2506503A1 (en) | 2004-06-03 |
| EP1567506A2 (en) | 2005-08-31 |
| EP1567506A4 (en) | 2007-06-20 |
| AU2003291394A1 (en) | 2004-06-15 |
| WO2004046101A3 (en) | 2004-09-16 |
| AU2003291394B2 (en) | 2009-06-25 |
| JP2006508979A (ja) | 2006-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4611745B2 (ja) | ＥｒｂＢ２及びＥＧＦＲ阻害剤としてのシアノグアニジン及びシアノアミジン | |
| US8088766B2 (en) | Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors | |
| CA2290918C (en) | Heteroaromatic bicyclic derivatives useful as anticancer agents | |
| JP5844284B2 (ja) | タンパク質キナーゼ阻害活性を有する二環式ヘテロアリール誘導体 | |
| JP6090801B2 (ja) | キナーゼ阻害剤としてのアミノキナゾリン | |
| JP5095626B2 (ja) | ピロロトリアジンキナーゼ阻害剤 | |
| ES2477878T3 (es) | Compuestos y composiciones de 5-(4-(aloalcoxi)fenil)pirimidin-2-amina como inhibidores de quinasas | |
| CN103097381B (zh) | 作为激酶抑制剂的1,8-萘啶物质 | |
| JP2021523159A (ja) | Ｅｒｂｂ受容体阻害剤 | |
| AU2001264159A1 (en) | Substituted bicyclic derivatives for the treatment of abnormal cell growth | |
| KR20050036984A (ko) | 항증식제로서 유용한 신규한 벤조이미다졸린 유도체 | |
| HRP20040529A2 (en) | Quinazoline derivatives for the treatment of abnormal cell growth | |
| US20100016307A1 (en) | Novel compounds | |
| CN108503627A (zh) | 用作egfr抑制剂的2,4-二取代苯-1,5-二胺衍生物及其应用 | |
| WO2020156283A1 (zh) | 炔基嘧啶或炔基吡啶类化合物、及其组合物与应用 | |
| WO2021129561A1 (zh) | 一种氰基取代吡啶及氰基取代嘧啶类化合物、制备方法及其应用 | |
| EP1396489A1 (en) | Heteroaromatic bicyclic derivatives useful as anticancer agents | |
| JP2002322178A (ja) | 二環式環基置換された４−アミノ−ピリドピリミジン誘導体 | |
| RU2810215C2 (ru) | Ингибиторы рецепторов erbb | |
| CN118221696A (zh) | 含有n-甲基哌嗪结构的嘧啶杂环类化合物及其制备方法和应用 | |
| JP5100639B2 (ja) | キナーゼ阻害剤としての置換７，８−ジヒドロ−１ｈ−ピリミド［４，５−ｂ］［１，４］ジアゼピン−４−アミン | |
| JP2023528927A (ja) | Ｆｒｓ２－ｆｇｆｒ相互作用の小分子阻害剤 | |
| CN118772111A (zh) | 一种取代的氨基嘧啶类化合物、药物组合物及其用途 | |
| KR20050073238A (ko) | 몰폴린기가 치환된 퀴나졸린 유도체 | |
| EA043330B1 (ru) | Новые антагонисты рецептора брадикинина |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060615 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060615 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091208 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100305 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100423 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100723 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100730 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100819 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20101001 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20101014 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131022 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 4611745 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |